IL307954A - Method for allowing immune cells infiltration in tumors - Google Patents
Method for allowing immune cells infiltration in tumorsInfo
- Publication number
- IL307954A IL307954A IL307954A IL30795423A IL307954A IL 307954 A IL307954 A IL 307954A IL 307954 A IL307954 A IL 307954A IL 30795423 A IL30795423 A IL 30795423A IL 307954 A IL307954 A IL 307954A
- Authority
- IL
- Israel
- Prior art keywords
- tumors
- immune cells
- cells infiltration
- allowing immune
- allowing
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000002865 immune cell Anatomy 0.000 title 1
- 230000008595 infiltration Effects 0.000 title 1
- 238000001764 infiltration Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2021/050572 WO2022226623A1 (en) | 2021-04-27 | 2021-04-27 | Method for allowing immune cells infiltration in tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307954A true IL307954A (en) | 2023-12-01 |
Family
ID=83846453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307954A IL307954A (en) | 2021-04-27 | 2021-04-27 | Method for allowing immune cells infiltration in tumors |
| IL307961A IL307961A (en) | 2021-04-27 | 2022-04-26 | Method for allowing immune cells infiltration in tumors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307961A IL307961A (en) | 2021-04-27 | 2022-04-26 | Method for allowing immune cells infiltration in tumors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240199758A1 (en) |
| EP (2) | EP4329801A1 (en) |
| JP (2) | JP2024516416A (en) |
| KR (2) | KR20240014052A (en) |
| CN (2) | CN117479955A (en) |
| AU (2) | AU2021442702A1 (en) |
| CA (2) | CA3173786A1 (en) |
| IL (2) | IL307954A (en) |
| MX (1) | MX2023012768A (en) |
| WO (2) | WO2022226623A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1882A (en) | 1872-12-11 | Angus. Campbell | A towel hanger | |
| EP1937815B1 (en) | 2005-09-13 | 2015-05-13 | National Research Council of Canada | Methods and compositions for modulating tumor cell activity |
| DK2504363T3 (en) | 2009-11-24 | 2019-07-29 | Alethia Biotherapeutics Inc | ANTI-CLUSTERIN ANTIBODIES AND ANTI-BINDING FRAGMENTS AND THEIR USE TO REDUCE TUMOR VOLUME |
-
2021
- 2021-04-27 IL IL307954A patent/IL307954A/en unknown
- 2021-04-27 WO PCT/CA2021/050572 patent/WO2022226623A1/en active Application Filing
- 2021-04-27 CN CN202180099369.0A patent/CN117479955A/en active Pending
- 2021-04-27 JP JP2023566662A patent/JP2024516416A/en active Pending
- 2021-04-27 EP EP21938161.3A patent/EP4329801A1/en active Pending
- 2021-04-27 US US18/287,327 patent/US20240199758A1/en active Pending
- 2021-04-27 CA CA3173786A patent/CA3173786A1/en active Pending
- 2021-04-27 KR KR1020237040576A patent/KR20240014052A/en active Search and Examination
- 2021-04-27 AU AU2021442702A patent/AU2021442702A1/en active Pending
-
2022
- 2022-04-26 EP EP22794137.4A patent/EP4329802A1/en active Pending
- 2022-04-26 KR KR1020237040565A patent/KR20240013743A/en unknown
- 2022-04-26 CN CN202280042256.1A patent/CN117479956A/en active Pending
- 2022-04-26 WO PCT/CA2022/050632 patent/WO2022226637A1/en active Application Filing
- 2022-04-26 AU AU2022266854A patent/AU2022266854A1/en active Pending
- 2022-04-26 MX MX2023012768A patent/MX2023012768A/en unknown
- 2022-04-26 JP JP2023565954A patent/JP2024516818A/en active Pending
- 2022-04-26 CA CA3173797A patent/CA3173797A1/en active Pending
- 2022-04-26 IL IL307961A patent/IL307961A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329801A1 (en) | 2024-03-06 |
| WO2022226623A1 (en) | 2022-11-03 |
| AU2022266854A1 (en) | 2023-11-30 |
| AU2022266854A9 (en) | 2023-12-07 |
| IL307961A (en) | 2023-12-01 |
| EP4329802A1 (en) | 2024-03-06 |
| JP2024516818A (en) | 2024-04-17 |
| CN117479955A (en) | 2024-01-30 |
| MX2023012768A (en) | 2023-11-13 |
| AU2021442702A1 (en) | 2023-11-30 |
| CN117479956A (en) | 2024-01-30 |
| CA3173786A1 (en) | 2022-10-27 |
| CA3173797A1 (en) | 2023-10-05 |
| US20240199758A1 (en) | 2024-06-20 |
| KR20240014052A (en) | 2024-01-31 |
| KR20240013743A (en) | 2024-01-30 |
| JP2024516416A (en) | 2024-04-15 |
| WO2022226637A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3906096A4 (en) | Methods and compositions for treating cancer with immune cells | |
| IL286183A (en) | Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment | |
| SG11202100125WA (en) | Method for editing dna in cell-free system | |
| SG11201700728WA (en) | Method for capturing rare cells in blood | |
| EP3400073A4 (en) | Implantable scaffolds for capturing metastatic breast cancer cells in vivo | |
| IL283043A (en) | Methods for shrinking pituitary tumors | |
| IL282531A (en) | Anti-liv1 immune cell cancer therapy | |
| SG11202012227PA (en) | Method for producing dental pulp-derived cells | |
| EP3928793A4 (en) | Method and composition for predicting long-term survival in cancer immunotherapy | |
| EP3243528A4 (en) | Method for inhibiting telomerase in cancer cells by means of luterion | |
| EP3834849A4 (en) | Method for treating tumor using immune effector cell | |
| IL287907A (en) | Methods for treating cancer | |
| ZA202100234B (en) | Methods and compositions using recombinant dendritic cells for cancer therapy | |
| ZA202102745B (en) | Anti-ptk7 immune cell cancer therapy | |
| EP3851543A4 (en) | Method for estimating breast cancer cell abundance | |
| EP3929629C0 (en) | Method for improving 2d seismic acquisition | |
| IL307961A (en) | Method for allowing immune cells infiltration in tumors | |
| EP4070810A4 (en) | Method for treating cancer using artificial adjuvant vector cells (aavc) | |
| EP3346015A4 (en) | Prognosis method for renal cell cancer | |
| EP3880216A4 (en) | Methods for treating cancer with manufactured t cells | |
| EP3778876A4 (en) | Method for promoting immune cell proliferation | |
| EP2689035A4 (en) | Method and kit for determining in vitro the probability for an individual to suffer from colorectal cancer | |
| SG11202104963WA (en) | Methods for manipulating cell state transitions in cancer | |
| GB201918313D0 (en) | Cells for treating cancer | |
| EP4048801A4 (en) | Conjugates and methods for treating acromegaly |